• News

Shanghai General Hospital Successfully Applies Genotype-Matched Platelet Transfusion to Treat High-Risk Pregnant Patient with Aplastic Anemia

Source: https://mp.weixin.qq.com/s/cLzgqb17_P2g9SLHGKs9Hg


The Department of Blood Transfusion at Shanghai General Hospital, in collaboration with the Shanghai Blood Center, has successfully provided genotype-matched platelet transfusion therapy to a high-risk pregnant patient with aplastic anemia. The treatment resulted in a significant increase in the patient’s platelet count, providing essential support for the safe termination of pregnancy and postoperative recovery. This successful case marks an important advance in the hospital’s management of complex transfusion cases and demonstrates its capability to address challenging cases of immune-mediated platelet transfusion refractoriness.

 

The patient, a young woman, was diagnosed with aplastic anemia around 2009 and began receiving treatment for the condition. Since then, she has relied on repeated blood product transfusions to maintain her platelet count. By the time she presented to Shanghai General Hospital, her platelet count was critically low, placing her at substantial risk of bleeding.

 

After becoming pregnant, the patient underwent conventional platelet transfusions at several hospitals, but her platelet count failed to show a significant improvement. Upon evaluation at Shanghai General Hospital, she was diagnosed with immune-mediated platelet transfusion refractoriness. As the pregnancy progressed, her risk of bleeding continued to rise. Continuing the pregnancy would also have placed additional demands on an already compromised hematopoietic system, potentially threatening her life. Following a multidisciplinary assessment, the medical team decided to perform a planned termination of pregnancy. Ensuring safe and effective platelet support throughout the perioperative period was identified as a critical factor in achieving a successful outcome.

 

According to Dr. Zhang Jun, Director of the Department of Blood Transfusion, platelet transfusion refractoriness remains a well-recognized challenge in clinical transfusion medicine, with immune-mediated mechanisms accounting for a major proportion of cases. Repeated platelet transfusions can lead to the development of alloantibodies against human leukocyte antigens (HLA) or human platelet antigens (HPA). These antibodies recognize and rapidly clear transfused platelets, preventing them from providing the intended hemostatic benefit.

 

Patients with aplastic anemia complicated by pregnancy may face particularly serious challenges because of the combined demands of pregnancy and underlying hematopoietic dysfunction. In cases of severe immune-mediated platelet transfusion refractoriness, conventional ABO-identical platelet transfusions or serological crossmatching alone may fail to achieve an adequate response.

 

Following the patient’s admission, the hospital promptly convened a multidisciplinary team to manage this high-risk obstetric case. The Department of Blood Transfusion activated its emergency protocol for complex transfusion cases and worked closely with the departments of obstetrics and hematology to assess the patient’s immune status and screen for platelet antibodies. Testing confirmed high levels of platelet alloantibodies, indicating that conventional compatibility-matching approaches were unlikely to provide effective transfusion support.

 

To address this critical challenge, the Department of Blood Transfusion worked closely with the Immunohematology Reference Laboratory of Shanghai Blood Center to perform high-resolution HLA and HPA genotyping. Based on the results, the team searched a registry of genotyped donors to identify a suitable match. A unit of apheresis platelets from a donor whose relevant HLA and HPA genotypes were fully compatible with those of the patient was identified. The product also tested negative in an immunohematological flow cytometry-based platelet crossmatch, supporting its suitability for transfusion.

 

Following transfusion of the genotype-matched platelets, the patient’s platelet count rose significantly within 24 hours. Her bleeding symptoms and risk of further bleeding were effectively controlled, and serial monitoring showed no rapid decline in platelet count. The clinical response met the treatment goals, providing reliable hemostatic support for the obstetric team to proceed with the planned termination of pregnancy. The patient recovered steadily after surgery, with her vital signs and laboratory results reaching clinically acceptable levels. She is now preparing for discharge.

 

Genotype-matched platelet transfusion is an important precision-based approach to managing platelet transfusion refractoriness. Unlike conventional ABO matching or serological crossmatching alone, this technique uses genetic testing to characterize a patient’s HLA and HPA genotypes and identify platelet donors with compatible genotypes. By improving donor selection in patients with clinically significant alloantibodies, the approach can increase the likelihood of an effective transfusion response and enhance transfusion safety. It may be particularly valuable for high-risk patients who require long-term, repeated transfusions, as well as those with immune-mediated complications or pregnancy complicated by hematological disorders.

 

As a key clinical support service, the Department of Blood Transfusion at Shanghai General Hospital has long been committed to developing advanced capabilities in complex transfusion medicine. The department routinely performs antibody screening, antiglobulin testing, platelet antibody screening, and platelet crossmatching. It has also established an ongoing collaborative mechanism with the Shanghai Blood Center for the investigation of complex blood group cases and the provision of specialized transfusion support.

 

The successful clinical application of genotype-matched platelets in this case further strengthens the hospital’s integrated approach to complex transfusion management, spanning antibody screening, genetic typing, and precision donor matching. This capability will support the hospital’s continued clinical development and help meet the transfusion needs of patients with complex medical conditions.

 

Looking ahead, the Department of Blood Transfusion will continue to deepen its technical collaboration with the Shanghai Blood Center, expand the clinical applications of genotype-matched platelet transfusion, and further improve rapid-response pathways for complex transfusion cases. Through more precise, safer, and more efficient transfusion services, the department aims to better protect the health and lives of patients.



Find a Doctor